Recent News

MD Biosciences announces the opening of a 20,000 square-foot state-of-the-art CNS research facility in Israel. The research facility contains  dedicated rodent and translational pig wings - both complete with surgical, treatment, and behavioral suites. State-of-the art electrophysiology, in vitro, and histology suites enable innovative study design with in vivo and ex vivo biomarker components. The translational pig wing includes open pen housing with play centers that promote social interactions and reduces environmental stress factors. 

Learn more about our state-of-the-art CNS research facility. 

Evaluating potential new therapies to treat post-operative pain (POP) is highly dependent on successful translation from animal models to humans. Pigs have several benefits over rodents including similar skin innervation to humans, which makes them a more rationale choice. The aim of this present study was to validate a POP model in Gottingen minipigs, as well as address some of the limitations reported using domestic pigs.

View Publication here

MD Biosciences Innovalora Ltd, Israel and Kahlo Sciences LLC dba MD Biosciences Neuro, launch new representative offices in Cambridge, MA, with the purpose of forging closer relationships and providing more access to Sponsors of contract research services.

Kahlo Sciences LLC, dba MD Biosciences Neuro will assume from MD Biosciences, Inc. all statements of work and master service agreements for services previously or currently in progress for CNS disease area services. The new presence will be an important base for our growing engagements and collaborations with members of the development community. We look forward to an exciting future where we can add even more significant value to the success and progress of our Sponsor programs.

MD Biosciences lab was featured with Ellegaard offering an exclusive expertise in pain studies. The article discusses our work to develop and validate models in adult pigs, specifically for chronic and acute pain. 

View Publication Here.

Due to the clinical and pathological similarities of experimental autoimmune encephalomyelitis (EAE) and Multiple Sclerosis (MS), EAE  is a model for the study of human demyelinating disease. Both EAE and MS are characterized by a relapsing-remitting disease course with subsequent progressive disability. EAE is characterized by chronic inflammatory demyelination of the central nervous system (CNS) and involves autoimmune CD4+ Th1 cells. These cells develop in the peripheral lymphoid organ and travel to the CNS causing an immune response. The development of T cells is controlled largely by the expression of various cytokines, as well as cellular adhesion molecules.

This past month in Paris, our scientists presented at the NeuroImmunology Conference, where they shared novel data in the Myelin Basic Protein (MBP) Induced model used to mimic Multiple Sclerosis (MS). This model is a powerful tool for studying disease pathogenesis as well as potential therapeutic interventions. Below find our poster data. 

When conducting MS research,  administration of one dose of MPB in a Lewis rat leads to a single relapse that is characterized by hind paw paralysis. This can be characterized histologically, by infiltration of mononuclear cells to the cervical spinal cord and formation of foci. This model is self-limiting and does not show demyelination.

View Data Here.

Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial later in the year for Alzheimer's. Using lead drug candidate EmtinB known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again in this study. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's.

View Press Here.

Despite massive investment in research for treatment options, there are not many effective and safe therapeutics for human chronic neuropathic pain (NP) afflictions. Options are limited due to the lack of translatable animal models, especially large animals who have similar physical and metabolic features to humans (Rice et al., 2008, Henze and Urban, 2010, Swindle et al., 2012). MD Biosciences, Inc. has developed a modified unilateral sciatic nerve PNT model in pigs that produces sustained NP behaviors consistent with those observed in human pain patients. The pig PNT model provides highly valuable data for translational pain research.

View Publication here.